U.S. Markets close in 18 mins.

Neurocrine Biosciences, Inc. (NBIX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
47.79+0.06 (+0.13%)
As of 3:42PM EDT. Market open.
People also watch
ALKSPGNXLGNDNKTRMDCO

Neurocrine Biosciences, Inc.

12780 El Camino Real
San Diego, CA 92130
United States
858-617-7600
http://www.neurocrine.com

SectorHealthcare
IndustryDrugs - Generic
Full Time Employees196

Key Executives

NameTitlePayExercisedAge
Dr. Kevin C. Gorman Ph.D.Chief Exec. Officer and Director972.52k337.25k59
Dr. Christopher F. O'Brien M.D.Chief Medical Officer758.71kN/A60
Dr. Haig P. Bozigian Ph.D.Chief Devel. Officer632.78kN/A59
Mr. Eric S. BenevichChief Commercial Officer607.86kN/A52
Mr. Timothy P. Coughlin CPAExec. Officer666.37kN/A50
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company’s lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women’s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia. In addition, the company’s research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women’s and men’s health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL – Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson’s disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Corporate Governance

Neurocrine Biosciences, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 4. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 7; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.